Biocon calls US generic drug tariffs a negotiation tactic
Biocon will wait before changing its US strategy, while exploring partnerships for local manufacturing if required, executive chairperson Kiran Mazumdar-Shaw told Mint. She said proposed tariffs were more likely a negotiating threat…
